End of the “golden dose”: Mounjaro pen update set to change what users see after fourth jab

For many users of Mounjaro, it became known online as the “golden dose” — the small amount of liquid often left in the KwikPen after the fourth and final prescribed injection.

Now, that leftover medicine is effectively being designed out.

Eli Lilly is introducing an updated version of its Mounjaro® (tirzepatide) KwikPen® in the UK from April 2026, in a move widely understood to bring an end to the unofficial practice of attempting to extract a fifth dose from a pen intended to deliver four.

While the pharmaceutical company has not explicitly framed the change around the so-called “golden dose”, the redesign focuses directly on reducing the amount of medicine left behind after the fourth weekly injection and making it much clearer when the pen has reached the end of its intended use.

What is the “golden dose”?

The “golden dose” is not an official medical term.

Instead, it emerged through social media discussions and online weight-loss communities as a nickname for the residual liquid that could remain visible in a Mounjaro KwikPen after all four prescribed doses had been administered.

Some users viewed this leftover liquid as an extra or “bonus” fifth injection.

However, clinicians, pharmacists and regulators have repeatedly warned that this is not a calibrated or approved dose, and should not be treated as one.

Experts have stressed that the excess solution is included as part of the device’s engineering tolerance to ensure the four prescribed doses can be accurately delivered and primed correctly.

It is not intended to provide a fifth weekly injection.

There have also been clear warnings around the risks of trying to extract this leftover medicine manually, including inaccurate dosing, contamination, infection, and increased side effects.

What is changing?

The old and new Mounjaro pens.

According to the manufacturer, the updated KwikPen has been modified to make treatment “simpler and easier to follow”, while keeping the patient experience exactly the same.

The main changes include:

• New plunger position

On unused pens, the plunger will now sit slightly further down inside the cartridge.

• Extended plunger design

A new internal component has been added to lengthen the plunger and help support accurate dose delivery.

• Clearer end-of-pen indicator

New Mounjaro pen with plunger at the end of the barrel

After the fourth dose, the plunger will sit close to the end of the cartridge, giving a clear visual indication that the pen is finished and ready for disposal.

This is the key design change that is expected to end the visible leftover medicine many users associated with the “golden dose”.

• What stays the same?

Crucially, the medicine itself is not changing.

Mounjaro remains tirzepatide, and the dosing schedule remains exactly the same.

Each pen will still deliver:

• four weekly doses

• 0.6 mL per dose

• one dose per week

The injection technique also remains unchanged.

Patients will use both the original and modified pens in exactly the same way.

The GTIN and PIP product codes also remain unchanged, meaning pharmacies will continue ordering in the same way during the transition.

UK rollout begins this month

The updated KwikPen is expected to begin appearing in the UK from April 2026.

During the transition period, patients may receive either the original version or the modified pen depending on existing pharmacy stock.

Both versions are expected to remain in circulation for a short period while older stock is used up.

That means some users may still temporarily see the previous design before the updated device becomes standard.

Why this is likely to draw attention

The redesign is likely to be closely watched by Mounjaro users, particularly private patients who have often discussed the financial impact of the treatment online.

With pens often costing significant amounts each month depending on strength and provider, the existence of leftover liquid had become a talking point among users seeking to maximise value.

But health professionals have consistently emphasised that only the four prescribed doses should be taken, and any remaining liquid should be discarded.

The new pen design now appears to align the device more clearly with that guidance, leaving far less room for confusion over whether anything remains after the final dose.

In practical terms, for patients, the message is simple: same medicine, same routine, same four weekly injections — but the “golden dose” era now appears to be coming to an end.

---

At a glance:

• Eli Lilly is introducing a modified Mounjaro KwikPen in the UK from April 2026

• The update is designed to reduce leftover medicine after the fourth dose

• The so-called “golden dose” or unofficial fifth dose is effectively being removed

• The medicine itself and the way patients use the pen remain unchanged

• Both old and new pens will be available during a short transition period

• Each pen will still deliver four weekly 0.6 mL doses